VANCOUVER, B.C. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--AlCana Technologies, Inc., The University of British Columbia, and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that Alnylam has elected to extend the companies’ RNAi therapeutics research collaboration for a third year. The research collaboration was initiated in August 2009 and focused on the discovery of novel cationic lipids employed in lipid nanoparticles (“LNPs”) for the systemic delivery of RNAi therapeutics.
